Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy
Abstract:
The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported. We regard the association recorded in this case to be a coincidence despite the known association between the drug and the development of immunosuppression and lymphoma. We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.
Related Concept Videos
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Therapeutic Drug Monitoring: Affecting Factors
Cryptococcal Meningitis


